Weak Q1 results, Semaglutide-related issues and cautious brokerage commentary weigh on investor sentiment as Dr. Reddy's ...

Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company' or 'Jyong Biotech'), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...

Founding member of the Alliance for Building Better Medicine celebrates Virginia-based End-to-End Commercialization Project as another step toward protecting America's medicine cabinet.RICHMOND, Va., ...

As generative AI captures public attention, a different kind of AI is reshaping drug discovery. Machine learning models are ...

Pakistan, July 23 -- Pakistan and China have signed 22 investment agreements worth approximately $629.5 million during the ...

U.S. Market to Reach USD 228.10 Million by 2035, While Europe Market to reach USD 1,255.74 Million, Advances with Sustainable ...

Samsung Biologics to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across US, Europe and India: Incheon, South Korea Thursday, July 23, 20 ...

Mustafa Kamal says agreements cover vaccine production, active pharmaceutical ingredients, medical devices and clinical trials ...

Can you tell us how many pens has Dr. Reddy able to sell during the quarter and a broad-based breakup regional-wise would be helpful. Yes. So we sold 180,000 pens before we stopped. We were supposed ...

Dr. Reddy''s Laboratories Ltd on Wednesday reported a 69 per cent year-on-year decline in consolidated profit after tax (PAT) attributable to equity holders at Rs 443.5 crore for the first quarter ...